Tag: Inventiva
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical study and provides an update on its clinical development program – 12/20/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), December 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: 43.8 million euros in cash, visibility expected until mid-2024
(AOF) – Inventiva publishes cash and cash equivalents at 43.8 million euros, compared to 86.7 million euros a year ago. The biotech specializing in the clinical development of small molecules…
Inventiva: financial visibility until the 3rd quarter of 2024
By Alexandra Saintpierre Published on 11/21/2023 at 10:24 p.m. Photo credit © Inventiva (Boursier.com) — The turnover ofInventive…
Inventiva publishes its financial information for the 3rd quarter of 2023 – 11/21/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), November 21, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces a late breaker abstract and two additional abstracts on its lead drug candidate, lanifibranor, at the Liver Meeting™ 2023 organized by the AASLD – 11/06/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), November 6, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: 31.2 million euros in cash, visibility until mid-2024 – 09/29/2023 at 09:54
(AOF) – Inventiva announces cash flow of 31.2 million euros as of June 30, 2023, compared to 86.7 million euros as of December 31, 2022. The biotech specializing in the…
Inventiva and Hepalys Pharma, Inc., sign an exclusive license agreement to develop and commercialize lanifibranor in Japan and South Korea – 09/20/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), Tokyo (Japan), September 20, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in clinical development…
Abnormal volumes on the Paris Stock Exchange: Inventiva, Chargeurs
During this trading session on Thursday August 31, 2023, particularly high trading volumes were detected on the French market. Today, it is the Inventiva share that stands out, with trading…
Inventiva: planned presentation at the 83rd Scientific Sessions of the American Diabetes Association
By Alexandra Saintpierre Published on 06/26/2023 at 07:24 Photo credit © Inventiva (Boursier.com) — inventive announces the selection…
Inventiva announces 5 scientific presentations at EASL INTERNATIONAL LIVER CONGRESS 2023
(Boursier.com) — inventive a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of nonalcoholic steatohepatitis and other diseases with unmet medical need, today…
Inventiva and Echosens launch a joint initiative to raise awareness about NASH and facilitate access to screening for patients at risk
By Claude Leguilloux Published on 08/06/2023 at 08:42 Photo credit © ChaunuPictures (Boursier.com) — inventive a biopharmaceutical company…
Inventiva joins forces with Echosens to raise awareness about Nash, liver disease – 06/08/2023 at 10:10
(AOF) – Inventiva joins forces with Echosens, the designer of Fibroscan, a diagnostic solution for liver health, to “raise awareness of NASH (non-alcoholic steatohepatitis) and facilitate access to screening for…